The current state of recombinant allergens for immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 6, 2010, Pages 575-581

  Pauli, Gabrielle ^a   Malling, H J ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Rigshospitalet   (Denmark)

Author keywords

allergen immunotherapy; hypoallergenic allergen derivatives; recombinant allergen vaccines; recombinant allergens; subcutaneous immunotherapy

Indexed keywords

POLLEN ANTIGEN; RECOMBINANT ALLERGEN; RECOMBINANT BIRCH ALLERGEN; RECOMBINANT GRASS ALLERGEN; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; BIRCH; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; HUMAN; HYPOTENSION; IMMUNOTHERAPY; NONHUMAN; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; SKIN ANAPHYLAXIS; URTICARIA;

ALLERGENS; ANIMALS; ANTIGENS, PLANT; BETULA; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; DISEASE PROGRESSION; HUMANS; HYPERSENSITIVITY; PHLEUM; RECOMBINANT PROTEINS;

EID: 78449257414     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833fd6c5     Document Type: Review

References (46)

1. Van Ree R,Chapman MD, Ferreira F, et al. The CREATEproject: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63:310-326.
2. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin immunol 2007; 119:826-830.
3. Vrtala S. Fromallergen genestonew forms of allergy diagnosis and treatment. Allergy 2008; 63:299-309.
4. Valenta R, Ferreira F, Focke-Tejkl M, et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-241.
5. Ferreira F, Wallner M, Breiteneder H, et al. Genetic engineering of allergens: future therapeutic products. Int Arch Allergy Immunol 2002; 128:171-178.
6. Vrtala S, Focke-Tejkl M, Swoboda I, et al. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 2004; 32:313-320.
7. Briner TJ, Kuo M, Keating KM, et al. Peripheral T-cell tolerance induced in näive and primed mice by sub-cutaneous injection of peptides from the major cat allergen Feld1.P Natl Acad Sci USA 1993; 90:7608-7616.
8. Hoyne GFR, O'Hehir DC, Wraith WR, et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in näive and sensitized mice. J Exp Med 1993; 178:1783-1788.
9. Hirahara K, Tatsuta T, Takatori T, et al. Preclinical evaluation of an immu-notherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001; 108:94-100.
10. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactivepeptides. Am J Respir Crit Care Med 1996; 154:1623-1628.
11. Simons FE, Imada M, Li Y, et al. Fed 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic subjects. Int Immunol 1996; 8:1937-1945.
12. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 2002; 360:47-53.
13. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Feld 1 derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-1274.
14. Larche M. Immunoregulation bytargetingTcellsinthetreatmentofallergyand asthma. Curr Opin Immunol 2006; 18:745-750.
15. Mueller U, Adkis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venum phospholipase A 2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-754.
16. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenecity and reduces its allergenicity. J Allergy Immunol 2000; 106:124-134.
17. Bohle B, Breitwieser A, Zwolfer B, et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial surface (S-layer) proteinand the majorbirch allergen Betv1 (rSbcC-Betv1) combines reduced allergenicity with immunomodulating capacity. J Immunol 2004; 172:6642-6648.
18. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a rag-weed-toll-like receptoragonistvaccineforallergic rhinitis. N Engl J Med 2006; 355:1445-1455.
19. Takai T, Yokota T, Yasue N, et al. Engineering of the major house dust mite allergen Derf2forallergen-specificimmunotherapy. Nature Biotechnol1997; 15:754-758.
20. Ferreira F, Ebner C, Kramer B, et al. Modulation of IgE reactivityofallergens by site-directed mutagenesis: potential use of hypoallergenic variants for im-munotherapy. FASEB J 1998; 12:231-242.
21. Holm J, Gajhede M, Ferreras M, et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE-binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 2004; 173:5258-5267.
22. Swoboda I, deWeerd N, Bhalla PL, et al. Mutantsof the majorryegrass pollen allergen, Lol p 5, with reduced IgE binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Biochem 2002; 32:295-302.
23. Drew AC, Eusebius NP, Kenins L, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173:5872-5889.
24. Orlandi A, Grasso F, Corinti S, et al. The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin Exp Allergy 2004; 34:470-477.
25. Mazaruela EG, Rodriguez R, Barber D, et al. Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin Exp Allergy 2006; 37:251-260.
26. Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005; 17:646-655.
27. Pauli G, Purohit A, Oster JP, et al. Comparison of genetically engineered hypoallergenic rBet v1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000; 30:1076-1084.
28. van Hage-Hamsten M, Kronqvist M, Zetterstrom O, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999; 104:969-977.
29. Gonzales-Rioja R, Ibarrola I, Arilla MC, et al. Genetically engineered hybrid proteins from Parietera judaica pollen for allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 120:602-609.
30. Jutel M, Jaeger L, Suck R, et al. Allergen specific immunotherapywith recombi-nantgrasspollenallergens. J Allergy Clin Immunol 2005; 116:608-613.
31. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-960.
32. Purohit A, Niederberger V, Kronqvist M, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38:1514-1525.
33. Klimek L, Bachert C, Doemer C, et al. Specific immunotherapy with recom-binant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int 2005; (Suppl N1):15.
34. Canonica GW, Baena-Cagnani, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324.
35. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21:77-83.
36. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53:461-472.
37. Bousquet J, Malling HJ, Locket RF, World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53 (Suppl 54):1-15.
38. James LK, Durham SR. Update on mechanisms of allergen injection immu-notherapy. Clin Exp Allergy 2008; 38:1074-1088.
39. van Hage-Hamsten M, Johansson E, Roquet A, et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp allergy 2002; 32:1448-1453.
40. Kettner J, Bachert C, Doemer C, et al. Specific immunotherapy with recom-binant birch pollen allergen rBet v1-FV is clinically efficacious-results of a phase III study. Allergy 2007; 62 (Suppl83):33. (Abst.81).
41. Niederberger V, Pauli G, Grönlund, et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera fromdifferentpopulations. J Allergy Clin Immunol 1998; 102:579-591.
42. Kündig TM, Senti G, Schnetzler G, et al. Der p 1 peptide onvirus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:1470-1476.
43. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Feld 1 onvirus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206:1941-1955.
44. Focke M, Linhart B, Hartl A, et al. Non anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v1, for preventive vaccination. Clin Exp Allergy 2004; 34:1525-1533.
45. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specificimmunoglobulin E and Tcell reactivity.Clin Exp Allergy 2010;40:385-397.
46. Edlmayer J, Niespodziana K, Linhart B, et al. Acombination vaccineforallergy and rhinovirus infections based on rhino-virus-derived protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen, Phl p1. J Immunol 2009; 182:6298-6306.